1. Scrip

After COVID-19 Vaccine Setbacks, GSK Expands Vir Antibody Pact

Companies’ Respiratory Deal Aims Beyond Coronavirus

 
• By Alaric DeArment

The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.

3D_Coronavirus
GSK is expanding its pact with Vir after setbacks on COVID-19 vaccines. • Source: Shutterstock

After encountering setbacks on the coronavirus vaccine front, GlaxoSmithKline plc is expanding an existing relationship with Vir Biotechnology, Inc. to develop antibodies for COVID-19 into territory beyond the pandemic.

London-based GSK and San Francisco-based Vir said on 17 February that they signed a binding agreement to expand the partnership they entered into last year around treatments for COVID-19 to include candidates for influenza and other respiratory viruses

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip